Korsana Biosciences

What Korsana Biosciences does

Korsana Biosciences is a clinical-stage biotechnology company founded in 2024 and headquartered in Waltham, Massachusetts, that develops antibody therapies for neurodegenerative diseases, beginning with Alzheimer's disease. The company is the seventh entity launched by venture creator Paragon Therapeutics (founded by Fairmount in 2021) and is pursuing an initial public listing via reverse merger with Cyclerion Therapeutics (Nasdaq: CYCN), expected to close in Q3 2026 under the ticker "KRSA." Korsana's addressable population is the Alzheimer's patient base in the United States, projected to reach approximately 13 million by 2050, an unmet need served by only two approved disease-modifying therapies since 2003, both limited by amyloid-related imaging abnormality (ARIA) risk and high-burden IV infusion plus MRI monitoring requirements.

The company's core technology is its proprietary Therapeutic Targeting (THETA™) blood-brain barrier-penetrant shuttle platform, developed in partnership with Paragon Therapeutics. THETA combines clinically validated transferrin receptor (TfR1) biology with proprietary Fc engineering and selective effector-function modulation, designed to ferry large-molecule biologics across the blood-brain barrier into the CNS at high concentrations while bypassing perivascular spaces around the choroid plexus to reduce ARIA risk. Its lead clinical asset, KRSA-028, is a next-generation anti-pyroglutamate (3pE) amyloid-beta monoclonal antibody that selectively targets plaque-enriched amyloid species, engineered for half-life extension and low-volume subcutaneous administration intended to eliminate infusion-center visits. Two additional undisclosed THETA-enabled programs sit at advanced and early discovery stages, targeting other high-unmet-need neurodegenerative indications and serving as platform validation beyond Alzheimer's.

As a pre-revenue clinical-stage biotech, Korsana's near-term economics are capital-driven rather than commercial. The company has raised $25 million in seed capital in 2024 from Fairmount and Venrock Healthcare Capital Partners and $150 million in a private Series A in September 2025 co-led by Wellington Management and TCGX, and is concurrently raising approximately $380 million in a private financing tied to the Cyclerion reverse merger (announced April 2026) — bringing total committed capital to roughly $555 million. These funds are earmarked for advancing KRSA-028 through Phase 1 healthy-volunteer data in mid-2027 and amyloid-plaque-clearance proof-of-concept in Alzheimer's patients by end of 2027, with stated runway into 2029. Future revenue, once products reach market, is expected to derive from direct commercialization and/or out-licensing of approved CNS biologics, with KRSA-028's subcutaneous design potentially bypassing the infusion-center infrastructure that constrains current anti-amyloid antibody franchises.

Name

Korsana Biosciences

Legal name

Korsana Biosciences, Inc.

Website

https://www.korsana.com

Company type

Private

Founded year

2024

Operating status

Operating

Headcount range

11–50 employees

Short description

Korsana Biosciences is a clinical-stage biotechnology company developing THETA-enabled, blood-brain barrier-penetrant antibody therapies for neurodegenerative diseases. Its lead candidate KRSA-028 is a subcutaneous anti-amyloid-beta monoclonal antibody designed to treat Alzheimer's disease with improved safety and convenience.

Ownership category

akta.pro rank

Product category

Biopharmaceuticals

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Biological Products, (No Disgnostic Substances) (2836)

akta.pro primary industry

Engineered Protein Therapeutics (de novo/AI-designed proteins, novel scaffolds) (HLAAAAAJ)

akta.pro secondary industries

Bispecific & Multispecific Antibodies (HLAAAAAF), Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB), Neurology/CNS Gene Therapies (HLAAACAH)

Keywords

• Neurodegenerative disease therapeutics
• Blood-brain barrier shuttle
• Monoclonal antibody therapy
• Alzheimer's disease treatment
• Central nervous system biologics

Headquarters

HQ city

Waltham

HQ country

United States

HQ region

North America

Offices3 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Pre-revenue clinical-stage biotech: Korsana is a clinical-stage biotechnology company that has not yet generated product revenue. The company is funded by venture capital (seed and Series A) and a concurrent private placement to support clinical development of KRSA-028 through 2027 milestones. Future revenue is expected to come from out-licensing or commercialization of approved therapies for neurodegenerative diseases.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels6 records

Core offering

Korsana Biosciences is a clinical-stage biotechnology company developing precision-engineered, blood-brain barrier (BBB)-penetrant antibody therapeutics for neurodegenerative diseases, starting with Alzheimer's. Its lead investigational candidate, KRSA-028, is a next-generation anti-3pE amyloid beta monoclonal antibody built on the proprietary Therapeutic Targeting (THETA™) BBB-shuttle platform, designed to increase amyloid plaque clearance, reduce ARIA risk, and enable low-volume subcutaneous administration.

Product overview

Korsana Biosciences operates a single, platform-plus-program architecture centered on its proprietary Therapeutic Targeting (THETA™) BBB-penetrant shuttle platform, which is the engine for the company's pipeline of neurodegenerative-disease biologics. The named product offerings on top of the THETA platform are the lead clinical-stage candidate KRSA-028 (a next-generation THETA-enabled anti-amyloid-β antibody for Alzheimer's disease) and two additional undisclosed THETA-enabled discovery-stage programs for other neurodegenerative diseases with high unmet need. The merger with Cyclerion Therapeutics (announced April 1, 2026, expected to close Q3 2026) will take the combined Korsana Biosciences, Inc. public on Nasdaq under ticker KRSA, with approximately $380M in concurrent private financing expected to fund operations into 2029.

Differentiator

Problem solved

Functional benefit

Brands

• THETA (Therapeutic Targeting): Korsana's proprietary blood-brain barrier-penetrant shuttle platform developed in partnership with Paragon Therapeutics.
• KRSA-028

Products and services

• KRSA-028

Quantifiable outcome

• Designed to reduce rate of amyloid-related imaging abnormalities (ARIA) and hematologic adverse events vs. first-generation anti-amyloid antibodies
• +2 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

Seven partnerships are on record, tiered flagship, core and minor.

• Cyclerion TherapeuticsflagshipStrategic or Co-development Partner · 1 April 2026Cyclerion Therapeutics (Nasdaq: CYCN) and Korsana entered into a definitive all-stock merger agreement on April 1, 2026; upon closing (expected Q3 2026), the combined company will operate as Korsana Biosciences, Inc. on Nasdaq under ticker KRSA. Pre-merger Cyclerion shareholders will own ~1.5% and Korsana stockholders ~98.5% of the combined company. Combined company will be led by Dr. Jonathan Violin with board chaired by Tomas Kiselak (Fairmount).
• Wedbush Securities Inc.coreOthers · 1 April 2026Wedbush Securities Inc. is serving as exclusive strategic financial advisor to Korsana on the Cyclerion merger; Wedbush & Co., LLC is also one of the placement agents to Korsana for the PIPE.
• Gibson, Dunn & Crutcher LLPcoreOthers · 1 April 2026Legal counsel to Korsana on the Cyclerion merger.
• Jefferies, TD Cowen, Stifel, UBS Investment BankcoreOthers · 1 April 2026Placement agents (alongside Wedbush & Co., LLC) to Korsana for the $380M PIPE.
• Cooley LLPcoreOthers · 1 April 2026Legal counsel to the placement agents on the $380M PIPE.
• Argot PartnersminorOthers · 1 April 2026Investor and media relations firm for Korsana (contact: 212-600-1902, [email protected]), per CFO appointment press release.
• Paragon TherapeuticsflagshipStrategic or Co-development Partner · 1 January 2024Paragon Therapeutics is Korsana's founding partner and the venture creator that discovered the assets (including KRSA-028) and co-developed the proprietary THETA™ blood-brain barrier shuttle platform. Korsana is the seventh company to launch with assets discovered and developed by Paragon, founded by Fairmount in 2021 and based in Waltham, MA. Paragon applies cutting-edge science to create complex biologics that are spun out into partner companies for clinical development.

Scale indicators9 records

Recent moves7 records

Expansion highlights6 records

Direct peers

• Denali Therapeutics: Clinical-stage biotech developing a TfR1-based BBB shuttle platform (TransportVehicle/OTV) to deliver large-molecule therapeutics across the blood-brain barrier. Most directly comparable to Korsana on both target shuttle biology and neurodegenerative disease focus.
• Voyager Therapeutics: Developer of AAV-based gene therapies with proprietary BBB-penetrant capsid engineering (TRACER platform) for CNS diseases. Closely comparable to Korsana on BBB-delivery innovation for CNS targets, though with a gene-therapy rather than antibody payload.
• Prothena: Clinical-stage biotech developing next-generation antibody therapeutics for amyloid-driven and neurodegenerative diseases, including anti-amyloid programs partnered with Bristol-Myers Squibb and Roche. Comparable in size, stage, and mechanistic approach.
• BioArctic: Swedish biotech that originated lecanemab (Leqembi) and is developing next-generation BBB-penetrant antibodies for Alzheimer's and other CNS diseases. Direct comparator on anti-amyloid BBB-shuttle antibody design.
• AC Immune: Clinical-stage biotech developing vaccines, antibodies, and small molecules for neurodegenerative diseases, including anti-amyloid programs (e.g., crenezumab legacy, ACI-35.080 anti-pTau vaccine). Directly comparable in therapeutic area and stage.

Emerging players

• Alnylam Pharmaceuticals: Leader in RNAi therapeutics actively extending into CNS via BBB-delivery collaborations (e.g., with Regeneron). Comparable to Korsana in targeting large-molecule delivery across the BBB, though with an siRNA rather than antibody payload.
• Cognition Therapeutics: Clinical-stage biotech developing small-molecule therapeutics for Alzheimer's disease and other neurodegenerative disorders. Comparable in clinical stage and Alzheimer's focus, though targeting a different (sigma-2 receptor) mechanism.

Broad incumbents

• Biogen: Co-developer of Leqembi (lecanemab) — one of only two approved anti-amyloid antibodies for Alzheimer's disease. A direct competitor to KRSA-028 in the disease-modifying Alzheimer's space and a broad incumbent in CNS therapeutics.
• Eli Lilly: Developer of Kisunla (donanemab), the second approved anti-amyloid antibody for Alzheimer's. Lilly is also pursuing next-generation CNS biologics and represents the most direct large-pharma competitor to Korsana's lead program.
• Roche / Genentech: Developing trontinemab, a Brainshuttle (TfR1-based) antibody targeting amyloid-beta for Alzheimer's. Direct overlap with Korsana on both BBB-shuttle technology and anti-amyloid target; broad CNS and large-molecule portfolio.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• LinkedInlinkedin.com/company/korsana-biosciences

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds3 records

Investors18 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A1 record

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Korsana Biosciences